We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session
Read MoreHide Full Article
Exelixis, Inc. (EXEL - Free Report) was a big mover last session, as the company saw its shares rise more than 17% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $23.35 to $28.27 in the past one-month time frame.
The move came after the company announced that its global phase 3 CELESTIAL trial met the primary endpoint to heal liver cancer patients with Cabometyx, which will provide significant improvement in comparison to placebo. Also, the company obtained the U.S. Food and Drug Administration approval for supplemental New Drug Application (sNDA) for the treatment of advanced renal cell carcinoma.
The company has seen one positive estimate revision in the past one month, while its Zacks Consensus Estimate for the current quarter has remained unchanged. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Exelixis currently has a Zacks Rank #3 (Hold), while its Earnings ESP is negative.
Is EXEL going up? Or down? Predict to see what others think: Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session
Exelixis, Inc. (EXEL - Free Report) was a big mover last session, as the company saw its shares rise more than 17% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $23.35 to $28.27 in the past one-month time frame.
The move came after the company announced that its global phase 3 CELESTIAL trial met the primary endpoint to heal liver cancer patients with Cabometyx, which will provide significant improvement in comparison to placebo. Also, the company obtained the U.S. Food and Drug Administration approval for supplemental New Drug Application (sNDA) for the treatment of advanced renal cell carcinoma.
The company has seen one positive estimate revision in the past one month, while its Zacks Consensus Estimate for the current quarter has remained unchanged. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Exelixis currently has a Zacks Rank #3 (Hold), while its Earnings ESP is negative.
Exelixis, Inc. Price
Exelixis, Inc. Price | Exelixis, Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Axovant Sciences Ltd. (AXON - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is EXEL going up? Or down? Predict to see what others think: Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>